Ⅲ期骨肉瘤的治疗

目的探讨Ⅲ期骨肉瘤的诊断、治疗和预后。方法分析1989年12月至2003年12月收治的23例Ⅲ期肢体骨肉瘤患者,男14例,女9例;年龄16～31岁,平均22.4岁。肺转移15例,骨转移7例(跳跃转移5例,骨肉瘤病2例),同时存在肺和骨转移1例。经术前化疗,并行原发肿瘤和转移病灶的切除手术。结果经术前化疗,1例就诊时肺部有1个结节的患者转移瘤消失,1例同时存在肺和骨转移者,切除原发病灶后,出现多处转移,不能行转移灶切除手术;2例骨肉瘤病者仅切除原发病灶;5例跳跃转移者中的2例,切除原发和跳跃转移病灶后,各出现1个肺转移灶。16例行开胸术,其中6例再次出现肺转移灶而行二次开胸术,3例患者二次开胸术后出现肺外转移而放弃治疗。原发病灶与转移病灶的肿瘤坏死率差异无统计学意义。随访5～168个月(平均74.6个月),无瘤生存9例,带瘤生存4例,死亡10例。Cox模型分析提示转移病灶的数目与预后相关(P<0.05)。肺转移与跳跃转移病灶的Kaplan-Meier生存曲线经log-rank检验,差异无统计学意义。结论新辅助化疗及原发病灶和转移灶的手术切除是Ⅲ期骨肉瘤治疗的有效方法,首次肺转移灶切除采用胸骨正中切口,转移瘤的数目与预后相关。     

单纯广泛切除肿瘤治疗低度恶性中心型成骨肉瘤——13例低度恶性中心型成骨肉瘤的诊治经验及文献回顾

[目的]低度恶性中心型成骨肉瘤是发生于骨髓腔的低度恶性成骨肉瘤,临床罕见。总结本中心收治的低度恶性中心型成骨肉瘤病例的诊治过程及经验。[方法]回顾本中心自1998年1月~2008年6月收治的13例低度恶性中心型成骨肉瘤。患者平均就诊年龄31岁。8例为初治病例,5例为外院手术后复发病例。后者中4例在外院行囊内手术,1例行边缘手术。Ⅰ期肿瘤11例,Ⅲ期肿瘤2例。Ⅰ期患者均首选肿瘤单纯广泛切除术。[结果]2例局部复发者术后病理分别为纤维肉瘤和恶性纤维组织细胞瘤。2例Ⅲ期患者转移灶术后病理均为低度恶性中心型成骨肉瘤。术后平均随访29个月。1例Ⅰ期肿瘤患者术后15个月出现肺转移,其接受综合治疗后已继续存活27个月。1例Ⅲ期患者术后26个月死亡,另1例术后随访6个月后失访。其余10例患者未发现局部复发、远处转移。保肢手术者,MSTS 93评分平均79%。[结论]低度恶性中心型成骨肉瘤患者多数只需要广泛切除、保肢治疗,无需化疗即可获得较长期的生存和较好的术后功能。手术切除边界不足依然是最终导致肿瘤复发的常见原因。长期随访是必要的。部分局部复发病灶可能表现为高度恶性肉瘤。少部分患者可能出现远处转移病灶,转移病灶病理可能依然表现为"高分化"。     

99例骨肉瘤肺转移患者随访结果分析

目的 了解骨肉瘤肺转移的预后情况,分析影响预后的因素.方法 回顾2000年1月至2008年7月治疗的99例骨肉瘤肺转移患者的临床资料,并对其预后进行随访,随访时间13～91个月,平均24.45个月.其中男65例,女34例;确诊时年龄7～68岁,平均20.39岁.患者均接受原发部位肿瘤切除治疗,93例患者接受新辅助化疗,6例因经济原因而未行其他辅助治疗.16例患者在就诊时即存在肺转移;47例在接受治疗期间发现肺转移,36例在随访期间发生肺转移.就发病年龄、肺转移数目、肺转移发生时段、合并其他部位的转移、原发肿瘤对化疗的反应、肺转移治疗等有可能影响预后的因素进行统计学分析.结果 从确诊骨肉瘤到发现肺转移时间为0～74个月,平均9.05个月.患者确诊骨肉瘤后的中位生存时间为25个月;累计一年、两年及五年生存率分别为87.4%、56.8%、23.4%.单因素统计分析显示骨肉瘤肺转移影响生存的有效预后因素为肺转移发生的时段及针对肺转移病灶的治疗;多因素统计分析显示肺转移发生的时段是影响预后的独立因素.其他因素如发病年龄、肺转移数目、合并其他部位的转移、原发肿瘤对化疗的反应等不具有统计学意义.结论 转移发生较晚且积极干预的骨肉瘤患者可获得较好的预后.对肺转移瘤进行积极的手术切除和辅助化疗能有效延长骨肉瘤肺转移患者的生存时间.     

99例骨肉瘤肺转移患者随访结果分析

目的 了解骨肉瘤肺转移的预后情况,分析影响预后的因素.方法 回顾2000年1月至2008年7月治疗的99例骨肉瘤肺转移患者的临床资料,并对其预后进行随访,随访时间13～91个月,平均24.45个月.其中男65例,女34例;确诊时年龄7～68岁,平均20.39岁.患者均接受原发部位肿瘤切除治疗,93例患者接受新辅助化疗,6例因经济原因而未行其他辅助治疗.16例患者在就诊时即存在肺转移;47例在接受治疗期间发现肺转移,36例在随访期间发生肺转移.就发病年龄、肺转移数目、肺转移发生时段、合并其他部位的转移、原发肿瘤对化疗的反应、肺转移治疗等有可能影响预后的因素进行统计学分析.结果 从确诊骨肉瘤到发现肺转移时间为0～74个月,平均9.05个月.患者确诊骨肉瘤后的中位生存时间为25个月;累计一年、两年及五年生存率分别为87.4%、56.8%、23.4%.单因素统计分析显示骨肉瘤肺转移影响生存的有效预后因素为肺转移发生的时段及针对肺转移病灶的治疗;多因素统计分析显示肺转移发生的时段是影响预后的独立因素.其他因素如发病年龄、肺转移数目、合并其他部位的转移、原发肿瘤对化疗的反应等不具有统计学意义.结论 转移发生较晚且积极干预的骨肉瘤患者可获得较好的预后.对肺转移瘤进行积极的手术切除和辅助化疗能有效延长骨肉瘤肺转移患者的生存时间.     

99例骨肉瘤肺转移患者随访结果分析

目的 了解骨肉瘤肺转移的预后情况,分析影响预后的因素.方法 回顾2000年1月至2008年7月治疗的99例骨肉瘤肺转移患者的临床资料,并对其预后进行随访,随访时间13～91个月,平均24.45个月.其中男65例,女34例;确诊时年龄7～68岁,平均20.39岁.患者均接受原发部位肿瘤切除治疗,93例患者接受新辅助化疗,6例因经济原因而未行其他辅助治疗.16例患者在就诊时即存在肺转移;47例在接受治疗期间发现肺转移,36例在随访期间发生肺转移.就发病年龄、肺转移数目、肺转移发生时段、合并其他部位的转移、原发肿瘤对化疗的反应、肺转移治疗等有可能影响预后的因素进行统计学分析.结果 从确诊骨肉瘤到发现肺转移时间为0～74个月,平均9.05个月.患者确诊骨肉瘤后的中位生存时间为25个月;累计一年、两年及五年生存率分别为87.4%、56.8%、23.4%.单因素统计分析显示骨肉瘤肺转移影响生存的有效预后因素为肺转移发生的时段及针对肺转移病灶的治疗;多因素统计分析显示肺转移发生的时段是影响预后的独立因素.其他因素如发病年龄、肺转移数目、合并其他部位的转移、原发肿瘤对化疗的反应等不具有统计学意义.结论 转移发生较晚且积极干预的骨肉瘤患者可获得较好的预后.对肺转移瘤进行积极的手术切除和辅助化疗能有效延长骨肉瘤肺转移患者的生存时间.     

老年骨肉瘤10例治疗总结

目的探讨老年骨肉瘤（≥60岁）的临床特点和治疗效果。 方法回顾性分析2007年1月至2017年3月期间山东大学齐鲁医院骨科收治的≥60岁的骨肉瘤患者10例,女性8例,男性2例,年龄60~76岁,平均（66±6）岁,病变位于股骨5例、踝关节软组织1例、多中心1例、骨盆（Ⅲ区）1例、肱骨1例、距骨1例。确诊后行截肢术2例,截肢术结合化疗2例,广泛切除术1例,广泛切除术结合化疗3例,边缘切除结合放疗1例,单纯化疗1例。 结果10例患者中,4例就诊时病史已超过6个月,2例就诊时已出现肺转移,5例合并基础疾病,2例血清ALP水平升高（>125 U/L）。影像学方面,7例为混合型,1例为溶骨型,1例为成骨型,1例位于软组织。肿瘤组织类型方面,普通型骨肉瘤7例,骨旁骨肉瘤2例,髓内高分化性骨肉瘤1例。10例患者随访3.5~124个月,平均（40±37）个月。1例接受单纯化疗的肺转移患者于明确诊断后3.5个月死亡,另1例肺转移患者接受转移灶射频消融术,随访58个月带瘤生存,1例距骨骨肉瘤复发后行截肢术。其余7例均未出现肿瘤复发或远处转移。 结论老年骨肉瘤临床较为少见,具有不同于青少年骨肉瘤的临床特点和预后,应早期明确诊断,采取适合患者自身情况的治疗方法,以尽可能降低复发和转移的发生率,延长生存期。     

三氧化二砷联合化疗治疗Ⅲ期成骨肉瘤、尤文肉瘤的初步报告

目的 探讨三氧化二砷（Arsenic trioxide,As2O3）联合化疗治疗转移性成骨肉瘤、尤文肉瘤的可行性。方法自2002年12月至2005年6月,32例转移性成骨肉瘤、尤文肉瘤患者接受了以三氧化二砷为主的二线化疗方案。其中男性19例,女性13例,年龄7～32岁。成骨肉瘤27例,尤文肉瘤5例;肿瘤转移部位包括肺转移25例,多发骨转移7例。所有病例均为手术后患者,术前及术后共接受过4～6周期的规范化疗。化疗方案：三氧化二砷、VP-16、紫杉醇。化疗2个周期28例,3个周期4例。结果所有患者均获得随访,随访时间6～36个月,平均20个月。经三氧化二砷联合化疗2个疗程后,5例完全缓解（15．6％）,转移病灶消失,无新发病灶出现;6例部分缓解（18．8％）;13例稳定（40．6％）,转移病灶无明显缩小,但出现明显钙化,其中完全钙化2例,部分钙化11例;8例进展（25％）,肿瘤体积增大或转移数目增多。21例治疗前碱性磷酸酶或乳酸脱氢酶增高的病例,9例（42．9％）明显下降。32例患者中病情持续稳定,肿瘤得到控制者24例,病情加重5例,死亡3例。结论三氧化二砷是一种低毒、有效的化疗药物,对于Ⅲ期成骨肉瘤、尤文肉瘤患者有较好的近期临床疗效。     

腓骨近端成骨肉瘤的外科治疗

目的 对腓骨近端成骨肉瘤患者的局部复发率和5年生存率进行评估.方法 1997年10月至2005年7月,12例腓骨近端成骨肉瘤患者中,男性9例,女性3例,平均年龄16岁(9～23岁).Enneking外科分期IIB期11例,III期1例.术前穿刺活检病理确诊后,除1例患者放弃治疗自动出院,其余11例均给予术前成骨肉瘤标准化大剂量化疗2个疗程后,手术切除肿瘤.按Malawer分型,I型切除8例,II型3例.术后继续进行术后化疗4个疗程,并定期复查.结果 仅有1例患者术后1年出现了局部复发,接受了再次手术切除,局部复发率为9%(1/11).确诊后自动出院的患者1年后死于双肺转移.III期1例患者半年后死于全身衰竭.2例IIB患者分别于术后1年和2年死于肺转移.12例患者获得随访,随访时间为6~117个月,平均60个月.11例患者Kaplan-Meier生存曲线5年生存率为72.7%.所有患者的膝关节功能稳定,腓总神经切除的患者术后带踝关节支架行走.结论 腓骨近端成骨肉瘤局部复发率较低,5年生存率和股骨远端和胫骨近端成骨肉瘤术后的基本相同.本研究证实对于腓骨近端肿瘤,边缘性切除并不影响腓骨近端成骨肉瘤的预后.术后外侧副韧带和股二头肌腱在胫骨近端外侧的止点重建对于膝关节的术后稳定性至关重要.     

儿童骨肉瘤的临床治疗

目的 探讨儿童骨肉瘤保肢手术的治疗方法。方法 8例儿童骨肉瘤，按Enneking外科分期属ⅡB期的四肢骨肉瘤。采用Rosen T12方案进行术前和术后化疗。结果 8例随访6个月—3年(平均30个月)，保肢手术患儿3年生存率明显提高。结论 儿童骨肉瘤明确诊断后，无论肿瘤切除或截肢，应用化疗是四肢骨肉瘤术前和术后治疗的最佳选择，它为骨肉瘤保肢提供条件，同时亦可提高生存率。     

骨膜骨肉瘤与高度恶性表面骨肉瘤

目的报告表面骨肉瘤的两种少见亚型,即骨膜骨肉瘤和高度恶性表面骨肉瘤的诊治经验。方法回顾 5例骨膜骨肉瘤和 4例高度恶性表面骨肉瘤患者的影像学和病理学特点,并对临床治疗结果进行分析。 5例骨膜骨肉瘤患者,男 1例,女 4例;年龄 28～ 42岁,平均 35岁;肿瘤位于胫骨上段者 4例,股骨下段者 1例。 4例高度恶性表面骨肉瘤患者,男 3例,女 1例;年龄 17～ 23岁,平均 19.25岁; 4例患者肿瘤均位于股骨下段。结果 5例骨膜骨肉瘤均予以广泛切除,除 1例因局部复发行截肢术,现无瘤生存 1年 3个月外,余 4例已无瘤生存 3～ 9年,平均 5年 9个月。 4例高度恶性表面骨肉瘤患者,虽经积极综合治疗,但仅 1例无瘤生存 7年; 1例术后 2年 5个月复发而截肢,现无瘤生存 1年 9个月; 1例于术后 2年 4个月死于肺转移;另 1例在确诊后 3个月死亡。结论骨膜骨肉瘤和高度恶性表面骨肉瘤各具鲜明的影像学和病理学特点,骨膜骨肉瘤恶性程度较低,应采用以局部广泛切除为主的手术治疗,预后相对较好;而高度恶性表面骨肉瘤的生物学行为则与经典的髓内骨肉瘤相似,预后较差,必须采用手术与化疗相结合的综合治疗方法。     

Multifocal osteosarcoma in childhood

Osteosarcoma is one of the most common primary malignant bone tumours in childhood, mainly affecting the metaphysis of long extremity bones. In rare cases, patients present at time of diagnosis with multiple bone lesions, sometimes in the absence of pulmonary metastases. The pathology pattern of these multifocal osteosarcomas occurring with a rare incidence of 0.5–4% is not yet clear, and in spite of investigations in diagnosis and therapy, the prognosis is still poor. We report two cases of multifocal synchronous osteosarcoma. The age of both children at the time of tumour detection was 14 years. A synchronous or metachronous occurrence of multiple bone lesions, initially in the absence of pulmonary metastases was seen. In both cases, treatment consisted of neoadjuvant chemotherapy, oncologic surgery and adjuvant chemotherapy. Tumour response to chemotherapy was good in one patient, and poor in the other case. In both patients initial R0-resection of the tumours was performed. The disease-free time was 1 year before detection of pulmonary metastases or relapse. By the combination of chemotherapy and aggressive surgery the prognosis in multifocal osteosarcoma has been improved over the last years. Nevertheless, the survival time is still short and seems to be correlated with the initial histological tumour response to chemotherapy.     

Treatment and prognosis for synchronous multifocal osteosarcoma in 42 patients

Between 1986 and 2002, 42 patients with synchronous multifocal osteosarcoma were treated with two different protocols of neoadjuvant chemotherapy. When feasible, the primary and secondary tumours were excised as a combined procedure. After initial chemotherapy 26 patients were excluded from simultaneous excision of all their secondary bone lesions as their disease was too advanced. In 12 patients only isolated excision of the primary lesion was possible. For 16 patients simultaneous operations were conducted to excise the primary and secondary lesions. This involved two supplementary sites in 15 patients and four additional sites in one patient. Of these, 15 attained remission but 12 relapsed and died (11 within two years). Three patients remained disease-free at five, six and 17 years. The histological response to pre-operative chemotherapy of the primary and secondary lesions was concordant in 13 of the 16 patients who underwent simultaneous operations at more than one site. The prognosis for synchronous multifocal osteosarcoma remains poor despite combined chemotherapy and surgery. The homogeneous histological responses in a large proportion of the primary and secondary lesions implies that synchronous multifocal osteosarcoma tumours are not multicentric in origin, but probably represent bone-to-bone metastases from a single tumour.     

Metachronous osteosarcoma: a report of five cases

Five patients with primary osteosarcoma who were treated effectively with chemotherapy and resective surgery and in whom a metachronous tumor subsequently developed in another site but who never had evidence of pulmonary metastases are described. The original bone scans of the five patients showed only the primary site as being involved. After diagnosis and treatment of the initial tumor, at intervals ranging from 12 to 78 months (average, 39 months) another osteosarcoma developed in the patients at a distant bony site. After diagnosis and treatment of the second osteosarcoma, followup of these patients for a mean of 77 months (range, 24-96 months) after the appearance of the metachronous tumor and for a mean of 118 months (range, 99-150 months) after the diagnosis of the primary lesion showed that none had pulmonary metastases develop. No recurrences of the local tumors have occurred and four of the patients currently are alive and free of disease. One of the patients had a fatal acute myelogenous leukemia develop 144 months after the discovery of the primary osteosarcoma and 86 months after the appearance of the metachronous disease. At the time of her death, however she had no evidence of osteosarcoma in any site.     

Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival

Treatment of adrenal metastases from cancer of the esophagogastric junction (EGJ) is not defined. The aim of the present work is to analyze retrospectively our experience in treating patients with adrenal metastases from EGJ adenocarcinoma. 102 patients with Siewert 1 or 2 EGJ adenocarcinoma underwent esophagectomy between May 2001 and Jan 2009. Five patients were diagnosed an adrenal metastases from EGJ adenocarcinoma, synchronous (s) in one and metachronous (m) in four, in the latter 11 months (mean) after esophagectomy. At diagnosis, three patients had synchronous metastases to mediastinal nodes (1 s and 2 m), 1 (m) had synchronous metastases to bone, and 1 (m) had an isolated adrenal metastasis. Three patients with synchronous node metastasis received chemotherapy followed by adrenalectomy 3, 8 and 16 months (mean 9) after diagnosis; one patient also received postoperative mediastinal radiotherapy. These patients are alive with no evidence of disease 16, 40 and 50 months after diagnosis of adrenal metastasis. The patient with bone metastasis received chemotherapy only and died 12 months after diagnosis of metastatic disease. The patient with isolated metastasis underwent laparoscopic adrenalectomy only, developed early bone metastases and died 15 months after surgery. In conclusion, our experience indicates that patients with adrenal metastases from adenocarcinoma of the EGJ may benefit from adrenalectomy if the gland is the only site of metastasis beyond lymphnodal disease. Chemotherapy should be considered before adrenalectomy to achieve better disease control and identify aggressive disease that would contraindicate adrenalectomy.     

Treatment recommendations for adrenal metastasis of non-small cell lung cancer

To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC. The patients included 12 males and 5 females with a mean age of 63.9 years. Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively. The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months. The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months. A survival analysis showed no significant prognostic difference between the patient age, gender, pathological stage, synchronous/metachronous classification, CEA, and site of metastases. However, patients who received an adrenalectomy had a more favorable prognosis. The 2-year survival of patients following resection versus those who did not undergo a resection for adrenal metastasis was 62.5 and 22.8%, respectively. These data indicate that metastatic adrenal tumors should be resected if the patient can tolerate surgery after appropriate selection.     

胃癌合并其他器官原发癌103例分析

目的探讨胃癌合并其他器官恶性肿瘤的发生率、临床病理特征及其诊治和预后情况。方法对我院1983年1月至2010年12月期间治疗的103例胃癌合并其他器官原发癌患者的临床病理资料进行回顾性分析。结果本组103例患者占同期收治胃癌患者的2.26%(103/4 552)。确诊胃癌的年龄为(63.98±11.93)岁(30～84岁)。同时多原发癌29例;异时多原发癌74例,其中胃癌确诊前异时多原发癌46例,胃癌确诊后异时多原发癌28例。共发生胃癌以外恶性肿瘤113个,以结直肠癌最多,占27.43%(31/113),肺癌其次,占15.04%(17/113)。异时癌的发生时间距胃癌确诊前或后(87.95±92.98)个月(7～506个月),65.49%(74/113)合并的原发癌距胃癌确诊的间隔时间在5年内。全组患者总的5年累积生存率为48.43%,其中同时多原发癌患者为36.40%,胃癌确诊前发生多原发癌者为42.31%,胃癌确诊后发生多原发癌者为69.52%,胃癌确诊后发生者的预后明显好于胃癌确诊前发生者和同时发生者(P<0.023,P<0.009)。在死亡原因明确的33例患者中有20例因胃癌死亡。结论胃癌治疗时需注意同时并发其他器官原发癌的可能,对于这类患者胃癌仍然可能是影响其预后的主要原因。     

多原发结直肠癌的临床病理特点

目的 总结多原发结直肠癌的临床病理特点.方法 回顾性分析2001年1月至2008年3月北京大学人民医院收治的30例多原发结直肠癌和580例单发结直肠癌患者的临床资料,30例多原发结直肠癌患者中同时性多原发癌(SC)16例,异时性多原发癌(MC)14例.计数资料采用x2检验,生存分析采用Kaplan-Meier法,生存率的比较采用Log-rank检验.结果 MC首发癌发病年龄早于SC和单发结直肠癌,而MC第二原发癌与SC和单发结直肠癌发病年龄接近.SC多位于左半结肠;MC首发癌以直肠、乙状结肠为多,第二原发癌以升结肠为主.SC和MC首发癌均行根治性切除,MC第二原发癌行根治性手术9例.除3例SC患者和2例MC患者未行化疗外,其余患者术后均接受FCF或FOLFOX或XELOX化疗方案治疗.单发结直肠癌患者中行根治性手术512例,姑息性手术68例,术后化疗519例,以FOLFOX或FCF或XELOX作为一线化疗方案.MC首发癌术后累积生存率明显高于单发结直肠癌(x2=17.289,P＜0.05),第二原发癌术后累积生存率与单发结直肠癌比较,差异无统计学意义(x2=1.731,P＞0.05).SC累积生存率与单发结直肠癌比较,差异无统计学意义(x2=0.800,P＞0.05).结论 MC预后优于单发结直肠癌,而SC预后与单发结直肠癌相当.

Abstract：

Objective To investigate the clinicopathological features of multiple primary colorectal carcinoma. Methods The clinical data of 30 patients with multiple primary colorectal carcinoma and 580 patients with single colorectal carcinoma who were admitted to the Peking University People's Hospital from January 2001 to March 2008 were retrospectively analyzed. There were 16 patients with multiple synchronous carcinoma and 14with multiple metachronous carcinoma. The survival of the patients was analyzed using Kaplan-Meier method and the survival rates were compared using Log-rank test. All data were analyzed using the chi-square test. Results The onset age of multiple metachronous primary carcinoma was younger than that of multiple synchronous carcinoma and single colorectal carcinoma, while the onset age of multiple metachronous secondary carcinoma was close to that of multiple synchronous carcinoma and single colorectal carcinoma. Most of the synchronous carcinoma located at the left colon; while most of the metachronous primary carcinoma located at the rectum and sigmoid colon, and most of the metachronous secondary carcinoma located at the ascending colon. Patients with multiple synchronous carcinoma or multiple metachronous primary carcinoma received radical resection. Of the 14 patients with multiple metachronous carcinoma, 9 received radical resection for secondary focus. Except for three patients with multiple synchronous carcinoma and two patients with multiple metachronous carcinoma, all patients received postoperative chemotherapy with FCF, FOLFOX or XELOX regimen. Of the 580 patients with single colorectal carcinoma, 512 received radical resection, 68 received palliative operation, and 519 received postoperative chemotherapy. The cumulative survival rate of patients with multiple metachronous primary carcinoma was significantly higher than that of single colorectal carcinoma (x2 = 17. 289, P ＜ 0. 05). There was no significant difference in the cumulative survival rate between patients with single colorectal carcinoma and those with multiple metachronous secondary carcinoma or multiple synchronous carcinoma (x2 = 1.731, 0. 800, P ＞ 0. 05). Conclusion The prognosis of patients with colorectal multiple metachronous carcinoma is better than those with single colorectal carcinoma, and the prognosis of colorectal synchronous carcinoma is similar to those with single colorectal carcinoma.     

胃癌肝转移患者的手术治疗及预后分析

目的探讨胃癌肝转移患者手术治疗的指征和效果。方法回顾性分析我院1995年9月至2002年5月间经手术治疗的43例胃癌肝转移患者的临床资料。结果全组肝转移程度与患者性别、年龄、肿瘤侵犯深度、分化程度及有无淋巴结转移无相关关系(P>0.05)。异时性肝转移行肝切除4例,中位生存时间为35.0个月,预后明显优于同时性肝转移肝切除患者(中位生存时间10.0个月)(P=0.0233)。同时性肝转移组中,单纯胃切除32例,中位生存时间6.0个月;胃加肝切除7例,中位生存时间10.0个月,两组差异无统计学意义(P=0.2799)。不同肝转移程度姑息性胃切除术后生存时间比较,H1、H2和H33组分别为7.5、6.0和4.0个月,差异具有统计学意义(P=0.0007)。结论异时性胃癌肝转移患者肝切除术后预后良好,应争取积极手术切除;胃癌肝转移患者同期行胃加肝切除生存率未见明显改善;H3肝转移患者姑息性胃切除预后不佳。     

Osteosarcoma: a review of 50 patients treated at the University of Alabama in Birmingham Medical Center between 1944 and 1975.

Only 12% of 50 patients lived 5 years or longer. Those who survived the longest were those with the tumor in the distal part of the lower extremity, with a well differentiated or chondroblastic tumor, or those who underwent radical surgery. Patients treated with surgery and chemotherapy lived about 1.5 months longer than those treated with sugery alone and about 1.2 months longer than those who had radiation included in the therapy. For a patient with a diagnosis of osteosarcoma, the prognosis was to be grave, no matter which methods of treatment were used.     

Peritoneal carcinomatosis from colorectal cancer

BACKGROUND: Aggressive therapeutic regimens have been advocated for the treatment of peritoneal carcinomatosis from colorectal cancer. It is essential to understand the clinical and histological features that govern the natural history of this condition if the efficacies of novel therapeutic approaches are to be assessed adequately. METHODS: A database of 3019 colorectal cancers was used to identify patients with synchronous peritoneal carcinomatosis, patients who developed metachronous peritoneal carcinomatosis, and those without carcinomatosis. Clinical, histological and survival data for the groups were collated and subjected to statistical analysis. RESULTS: Some 349 patients (13 per cent) with peritoneal carcinomatosis were identified; 214 had synchronous disease and 135 had metachronous carcinomatosis. Some 125 patients (58 per cent) in the synchronous group were free of systemic metastases; 80 of these patients had localized disease. Liver metastases, tumour (T) stage, nodal stage, and venous and perineural invasion were independent predictors of metachronous carcinomatosis. The median survival of patients with synchronous disease was 7 months; survival was adversely affected by the extent of peritoneal carcinomatosis and the T stage of the primary cancer. CONCLUSION: Peritoneal carcinomatosis is a common mode of disease progression in patients with colorectal cancer. For the majority of patients the prognosis is poor, but a small number with localized disease may be suitable for further aggressive therapy.